CUTIA-B Shares Climb Over 3% Following Completion of Phase III Trial for Injectable Botulinum Toxin
Stock News
Apr 13
CUTIA-B (02487) rose more than 3% during trading. At the time of writing, the stock was up 3.25%, trading at HK$4.76, with a turnover of HK$409,900.
The company announced the completion of its Chinese Phase III clinical trial for CU-20101, an injectable Type A botulinum toxin intended to improve moderate to severe glabellar lines. The trial was designed to evaluate the efficacy and safety of both single and repeated injections of CU-20101 for treating moderate to severe glabellar lines. The study used the reference product BOTOX® (onabotulinumtoxinA) as a control.
All participants completed the trial in November 2025, and the database was locked in January 2026, with positive topline results achieved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.